SK Biopharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
SK Biopharmaceuticals has a total shareholder equity of ₩340.1B and total debt of ₩171.5B, which brings its debt-to-equity ratio to 50.4%. Its total assets and total liabilities are ₩791.5B and ₩451.4B respectively.
Key information
50.4%
Debt to equity ratio
₩171.46b
Debt
Interest coverage ratio | n/a |
Cash | ₩291.05b |
Equity | ₩340.07b |
Total liabilities | ₩451.42b |
Total assets | ₩791.49b |
Recent financial health updates
Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn
Mar 12Recent updates
Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27We're Not Worried About SK Biopharmaceuticals' (KRX:326030) Cash Burn
Mar 12Financial Position Analysis
Short Term Liabilities: A326030's short term assets (₩555.8B) exceed its short term liabilities (₩355.4B).
Long Term Liabilities: A326030's short term assets (₩555.8B) exceed its long term liabilities (₩96.0B).
Debt to Equity History and Analysis
Debt Level: A326030 has more cash than its total debt.
Reducing Debt: A326030's debt to equity ratio has reduced from 65.6% to 50.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A326030 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A326030 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.